Advertisement

Picture ConsulTech GmbH GDPR-compliant E-Col Cloud Document Management 650x80px
Document › Details

Hookipa Pharma Inc.. (10/6/21). "Press Release: Groundbreaking Ceremony for Hookpia’s New Production Site". Vienna.

Region Region Wien (Vienna)
  Country Austria
Organisations Organisation Hookipa Pharma Inc. (Nasdaq: HOOK)
  Group Hookipa (Group)
  Organisation 2 Wien (Vienna) (govt region)
Products Product cancer immunotherapy (immuno-oncology, I-O)
  Product 2 biopharmaceutical production
     


HOOKIPA Pharma Inc. (NASDAQ: HOOK), a company that has been fighting cancer and serious immune diseases for ten years, is setting up its own production site in aspern Seestadt in Vienna. In the presence of the City Councilor for Economic and Financial Affairs Peter Hanke, the Donaustadt District Chairman Ernst Nevrivy, Gerhard Schuster (Chairman of the Vienna 3420 Aspern Development AG) and Roman Necina (CTO HOOKIPA Pharma), the groundbreaking ceremony marked the successful start of this project.

The decision to have its own PLANT production facility in Vienna is another pioneering step for the biotech company HOOKIPA, which is headquartered at the Vienna BioCenter in St. Marx and is celebrating its tenth birthday this year. For Roman Necina, CTO of HOOKIPA Pharma, the reasons for setting up the new production site in Vienna are obvious: Proximity to our arena virus experts in St. Marx is decisive for the choice of location. In aspern Seestadt we find optimal and future-oriented framework conditions for our first own production site. “


Production site creates up to 100 new jobs

In the first stage of expansion, HOOKIPA is building a production building with quality control laboratories and office areas on an area of ??4,500 m2 in Seestadt. In a further expansion stage, the location will be expanded to include an additional production building and a multifunctional building with research and development laboratories.

“With the choice of location, we are sending a strong signal for Vienna as a business and research location. In a first step we will create up to 60 new jobs here, and for full operation we want to increase the number of employees in production to a total of 100 ”, adds Necina.

“The settlement of HOOKIPA in the Seestadt Aspern proves Vienna’s high standing in the international ranking of biotech locations. Together with the business agency, the City of Vienna has been implementing numerous funding measures for many years to offer biotech companies optimal framework conditions and thus to create future-proof, highly qualified jobs – such as at the Vienna BioCenter in St. Marx. With the new HOOKIPA location, Vienna is now experiencing a further upgrade, ”said Vienna City Councilor for Economics and Finance Peter Hanke.


The value chain remains largely in Austria

“The settlement of the promising and innovative company HOOKIPA in the Seestadt Aspern is a further enrichment for this business location. With the construction of this production facility, numerous jobs will be created in the Danube city in the coming years. I am convinced that the biotech company’s decision in favor of this top location is a good investment, ”says Ernst Nevviry, District Chairman of Vienna-Donaustadt, confidently.

Gerhard Schuster, CEO of Seestädter Entwicklungsgesellschaft Wien 3420 aspern Development AG, picks up on this: “Future-oriented companies like HOOKIPA find optimal conditions for research and development as well as production in urban areas in aspern Seestadt – numerous companies have already found their place here. I am convinced that our network will benefit from HOOKIPA just as the company itself will benefit from its new location. “

At the newly built production site, viral vectors as well as clinical material and commercial products are manufactured on an industrial scale. “With the exception of the filling of the substances, the entire process chain will be processed in the new facility. This means that a large part of the added value remains in Austria, ”says Necina. Only the bottling takes place in Germany.


HOOKIPA develops a new class of immunotherapies

With currently around 130 employees in Vienna and New York, an IPO on the Nasdaq in 2019 and several financing rounds, HOOKIPA is one of the leading biopharmaceutical companies. The Vienna-based biopharmaceutical company HOOKIPA is developing a new class of immunotherapies to combat cancer and infectious diseases more effectively. These immunotherapeutics are based on a proprietary arenavirus platform and are designed to reprogram the body’s immune system. Not only cancer, but also HIV, hepatitis B and other serious diseases could be treated much more efficiently in the future.

At the moment, all production and test activities have been outsourced, which is associated with considerable costs, little flexibility in capacity planning and a high production risk. “With the construction of PLANT, we can cut costs in the long term, reduce development cycles and prevent supply bottlenecks. In addition, the learning curve remains in the company, which will give us a competitive advantage over the next few years, ”concludes Necina.


About HOOKIPA

Founded in Vienna in 2011, HOOKIPA Pharma Inc. (NASDAQ: HOOK) is a clinical-stage biopharmaceutical company developing a new class of immunotherapeutic drugs based on its proprietary arenavirus platform that reprogram the body’s immune system. HOOKIPA’s proprietary arenavirus-based technologies, non-replicating and replicating, induce robust antigen-specific CD8 + T cells and pathogen-neutralizing antibodies. HOOKIPA’s viral vectors target antigen presenting cells in vivo to activate the immune system. Both technologies allow repeated administration to boost and rejuvenate the immune response.

   
Record changed: 2021-10-19

Advertisement

Picture EBD Group Connector Personal Networking in Life Sciences 650x80

More documents for Hookipa (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture ConsulTech GmbH GDPR-compliant E-Col Cloud Document Management 650x80px




» top